Piper Sandler Sticks to Its Buy Rating for Minerva Surgical (UTRS)
Piper Sandler Adjusts Minerva Surgical's Price Target to $1 From $5, Keeps Overweight Rating
Piper Sandler Maintains Overweight on Minerva Surgical, Lowers Price Target to $1
Piper Sandler Remains a Buy on Minerva Surgical (UTRS)
Analysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and Minerva Surgical (UTRS)
Minerva Surgical (UTRS) Was Downgraded to a Sell Rating at J.P. Morgan
Analysts Conflicted on These Healthcare Names: Replimune Group (REPL), Minerva Surgical (UTRS) and Nektar Therapeutics (NKTR)
J.P. Morgan Downgrades Minerva Surgical (UTRS) to a Sell
Minerva Surgical Is Maintained at Overweight by Piper Sandler
Minerva Surgical Price Target Cut to $5.00/Share From $6.00 by Piper Sandler
Piper Sandler Maintains Overweight on Minerva Surgical, Lowers Price Target to $5
Piper Sandler Adjusts Minerva Surgical's Price Target to $5 From $6, Reiterates Overweight Rating
Minerva Surgical Cut to Underweight From Overweight by JP Morgan
Minerva Surgical analyst ratings